

**Funding:**

Part of this work was supported by the European Community's Seventh Framework Programme under grant agreement number 223175 (HEALTH-F2-2009-223175). The Breast Cancer Association Consortium is funded by Cancer Research UK (CR-UK) (C1287/A10118, C1287/A12014). Meetings of the 14 Breast Cancer Association Consortium have been funded by the European Cooperation in Science and Technology (COST) programme (BM0606). DFE is a Principal Research Fellow of CR-UK. The CNIO-Breast Cancer Study was supported by the Genome Spain Foundation, the Red Temática de Investigación Cooperativa en Cáncer and grants from the Asociación Española Contra el Cáncer and the Fondo de Investigación Sanitario (PI081120 to JB, PI081583 to RLM). The Polish Breast Cancer Study was funded by Intramural Research Funds of the National Cancer Institute, Department of Health and Human Services, USA. The Kuopio Breast Cancer Project was financially supported by the special Government Funding (EVO) of Kuopio University Hospital grants, the Cancer Fund of North Savo, the Finnish Cancer Organisations, the Academy of Finland and by the strategic funding of the University of Eastern Finland. The Helsinki Breast Cancer Study has been financially supported by the Helsinki University Central Hospital Research Fund, the Academy of Finland (132473), the Finnish Cancer Society and the Sigrid Juselius Foundation. The UCI Breast Cancer Study component of this research was supported by the US National Institutes of Health (NIH) (CA58860 and CA92044) and the Lon V Smith Foundation (LVS39420). The Leiden University Medical Centre Breast Cancer Study (ORIGO) study was supported by the Dutch Cancer Society. The Singapore and Sweden Breast Cancer Study was supported by the Agency for Science, Technology and Research of Singapore, the US NIH and the Susan G. Komen Breast Cancer Foundation. The Seoul Breast Cancer Study was supported by the Korea Health 21 R&D Project (AO30001), Ministry of Health and Welfare, Republic of Korea. The Mayo Clinic Breast Cancer Study was supported by the NIH (CA122340 and CA128978) and the Mayo Clinic Breast Cancer SPORE (CA116201). The Copenhagen General Population Study was supported by the Chief Physician Johan Boserup and Lise Boserup Fund, the Danish Medical Research Council and Herlev Hospital. The Karolinska Breast Cancer Study was supported by the Swedish Cancer Society, the Swedish Gustav V Jubilee Foundation, the Bert von Kantzows Foundation and the

Stockholm Cancer Foundation. The work of the Bavarian Breast Cancer Cases and Controls was partly funded by ELAN-Fond of the University Hospital of Erlangen. The Genetic Epidemiology Study of Breast Cancer by Age 50 was supported by the Deutsche Krebshilfe e.V. (70492), and genotyping was supported in part by the state of Baden-Württemberg through the Medical Faculty of the University of Ulm (P.685). The Taiwanese Breast Cancer Study is supported by the Taiwan Biobank project of the Institute of Biomedical Sciences, Academia Sinica, Taiwan.

Infrastructure support for the Melbourne Collaborative Cohort Study recruitment and follow-up is provided by Cancer Council Victoria, while cohort recruitment was partly funded by VicHealth. This work, which used the Melbourne Collaborative Cohort Study, was supported by the Australian National Health and Medical Research Council (NHMRC) (grants 209057, 251533 and 396414). The Sheffield Breast Cancer Study was supported by Yorkshire Cancer Research and the Breast Cancer Campaign. The Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer is supported by grants from the National Breast Cancer Foundation; the NHMRC of Australia; the Queensland Cancer Fund; the Cancer Councils of New South Wales, Victoria, Tasmania and South Australia; and the Cancer Foundation of Western Australia. The Kathleen Cuninghame Foundation Consortium for Research into Familial Breast Cancer Clinical Follow-Up Study was funded by the NHMRC (grants 145684, 288704 and 454508). Financial support for the Australian Ovarian Cancer Study was provided by the US Army Medical Research and Materiel Command (DAMD17-01-1-0729), the Cancer Council of Tasmania and Cancer Foundation of Western Australia and the NHMRC (199600). GCT is supported by the NHMRC. The British Breast Cancer Study is funded by CR-UK and Breakthrough Breast Cancer and acknowledges National Health Service funding to the National Institute for Health Research Biomedical Research Centre and the National Cancer Research Network. The German Familial Breast Cancer Study was supported by the Deutsche Krebshilfe (107054), the Center of Molecular Medicine Cologne and the Helmholtz Society. BB was supported by the Dietmar Hopp Foundation. The Mammary Carcinoma Risk Factor Investigation study was supported by the Deutsche Krebshilfe e.V. (70-2892-BR I), the Hamburg Cancer Society and the German Cancer Research Center, and genotyping was supported in part by the

Federal Ministry of Education and Research, Germany (01KH0402). The Australian Breast Cancer Family Study was supported by the NHMRC of Australia (145604), the NIH (CA102740-01A2) and the US National Cancer Institute, NIH (CA-95-011), through cooperative agreements with the members of the Breast Cancer Family Registry (BCFR) and principal investigators from Cancer Care Ontario (CA69467), Columbia University (CA69398), Fox Chase Cancer Center (CA69631), Huntsman Cancer Institute (CA69446), Northern California Cancer Center (CA69417) and The University of Melbourne (CA69638). The content of this article does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centres in the BCFR, nor does mention of trade names, commercial products or organisations imply endorsement by the US Government or the BCFR. The Australian Breast Cancer Family Study was initially supported by the NHMRC, the New South Wales Cancer Council and the Victorian Health Promotion Foundation. JLH is an Australia Fellow of the NHMRC and a Victorian Breast Cancer Research Consortium Group Leader. MCS is a Senior Research Fellow of the NHMRC. The Study of Epidemiology and Risk Factors in Cancer Heredity (SEARCH) is funded by a programme grant from CR-UK (C490/A10124). The Gene Environment Interaction and Breast Cancer in Germany study was supported by the German Human Genome Project and funded by the Federal Ministry of Education and Research (01KW9975/5, 01KW9976/8, 01KW9977/0 and 01KW0114).